MAFB and MAF Transcription Factors as Macrophage Checkpoints for COVID-19 Severity

Miguel A Vega1, Miriam Simón-Fuentes1, Arturo González de la Aleja1

  • 1Myeloid Cell Laboratory, Centro de Investigaciones Biológicas Margarita Salas, CSIC, Madrid, Spain.

Frontiers in Immunology
|December 14, 2020
PubMed

Insights

In severe COVID-19, altered macrophage responses involve transcription factors MAFB and MAF. A high MAFB/MAF ratio may diagnose disease progression and guide therapeutic strategies to restore immune function.

Area of Science:

  • Immunology
  • Molecular Biology
  • Virology

Background:

  • Severe COVID-19 is characterized by impaired interferon (IFN) production and heightened inflammatory and pro-fibrotic responses.
  • Macrophages play a critical role in COVID-19 pathogenesis, with specific pathogenic subsets identified in severe cases.

Purpose of the Study:

  • To investigate the role of transcription factors MAFB and MAF in shaping macrophage responses to SARS-CoV-2.
  • To explore the potential of the MAFB/MAF expression ratio as a diagnostic marker and therapeutic target for severe COVID-19.

Main Methods:

  • Analysis of MAFB and MAF expression in relation to clinical and biological features of severe COVID-19.
  • Evaluation of the impact of MAFB/MAF ratio on macrophage transcriptional signatures and responses to SARS-CoV-2.

Main Results:

  • Evidence links MAFB overexpression and MAF silencing to severe COVID-19 clinical and biological characteristics.
  • A high MAFB/MAF expression ratio in lung macrophages correlates with COVID-19 progression.

Conclusions:

  • The MAFB/MAF expression ratio in macrophages may serve as a diagnostic tool for COVID-19 severity.
  • Modulating this ratio could restore IFN production and reduce inflammation and fibrosis, offering a potential therapeutic strategy.